L
Lynn M. Schuchter
Researcher at University of Pennsylvania
Publications - 255
Citations - 27393
Lynn M. Schuchter is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 69, co-authored 236 publications receiving 22615 citations. Previous affiliations of Lynn M. Schuchter include Johns Hopkins University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty,J. R. Infante,Adil Daud,Rene Gonzalez,Richard F. Kefford,Jeffrey A. Sosman,Omid Hamid,Lynn M. Schuchter,Jonathan Cebon,Nageatte Ibrahim,Ragini Kudchadkar,Howard A. Burris,Gerald S. Falchook,Alain Algazi,Karl D. Lewis,Georgina V. Long,Igor Puzanov,Peter F. Lebowitz,Ajay Singh,Shonda M Little,Peng Sun,Alicia Allred,Daniele Ouellet,Kevin B. Kim,Kiran Patel,Jeffrey S. Weber +25 more
TL;DR: Dabrafenib and trametinib were safely combined at full monotherapy doses, and the rate of pyrexia was increased with combination therapy, whereas the rates of proliferative skin lesions was nonsignificantly reduced.
Journal ArticleDOI
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman,Kevin B. Kim,Lynn M. Schuchter,Rene Gonzalez,Anna C. Pavlick,Jeffrey S. Weber,Grant A. McArthur,Thomas E. Hutson,Stergios J. Moschos,Keith T. Flaherty,Peter Hersey,Richard F. Kefford,Donald P. Lawrence,Igor Puzanov,Karl D. Lewis,Ravi K. Amaravadi,Bartosz Chmielowski,H. Jeffrey Lawrence,Yu Shyr,Fei Ye,Jiang Li,K. B. Nolop,Richard J. Lee,Andrew K. Joe,Antoni Ribas +24 more
TL;DR: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma, and the median overall survival in this study with a long follow-up was approximately 16 months.
Journal ArticleDOI
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor,Andrew J. Rech,Amit Maity,Ramesh Rengan,Ramesh Rengan,Kristen E. Pauken,Erietta Stelekati,Joseph L. Benci,Bihui Xu,Hannah Dada,Pamela M. Odorizzi,Ramin S. Herati,Kathleen D. Mansfield,Dana Patsch,Ravi K. Amaravadi,Lynn M. Schuchter,Hemant Ishwaran,Rosemarie Mick,Daniel A. Pryma,Xiaowei Xu,Michael Feldman,Tara C. Gangadhar,Stephen M. Hahn,E. John Wherry,Robert H. Vonderheide,Andy J. Minn +25 more
TL;DR: Major tumour regressions are reported in a subset of patients with metastatic melanoma treated with an anti-CTLA4 antibody and radiation and reproduced this effect in mouse models, showing that PD-L1 on melanoma cells allows tumours to escape anti- NCTLA4-based therapy, and the combination of radiation, anti- CTLA4 and anti-PD-L 1 promotes response and immunity through distinct mechanisms.
Journal ArticleDOI
Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response
Chen Gang,Alexander C. Huang,Wei Zhang,Wei Zhang,Gao Zhang,Wu Min,Wei Xu,Zi-Li Yu,Jiegang Yang,Jiegang Yang,Beike Wang,Beike Wang,Honghong Sun,Hou-Fu Xia,Qiwen Man,Wenqun Zhong,Wenqun Zhong,Leonardo F. Antelo,Bin Wu,Xuepeng Xiong,Xiaoming Liu,Lei Guan,Lei Guan,Ting Li,Ting Li,Shujing Liu,Ruifeng Yang,Youtao Lu,Liyun Dong,Suzanne McGettigan,Rajasekharan Somasundaram,Ravi Radhakrishnan,Gordon B. Mills,Yiling Lu,Junhyong Kim,Youhai H. Chen,Haidong Dong,Yi-Fang Zhao,Giorgos C. Karakousis,Tara C. Mitchell,Lynn M. Schuchter,Meenhard Herlyn,E. John Wherry,Xiaowei Xu,Wei Guo +44 more
TL;DR: It is reported that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface, suggesting a mechanism by which tumours could evade the immunesystem, and the potential application ofExosomal PD- L1 to monitor patient responses to checkpoint therapies.
Journal ArticleDOI
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang,Michael A. Postow,Michael A. Postow,Robert J. Orlowski,Rosemarie Mick,Bertram Bengsch,Sasikanth Manne,Wei Xu,Shannon Harmon,Josephine R. Giles,Brandon Wenz,Matthew Adamow,Deborah Kuk,Katherine S. Panageas,Cristina Carrera,Cristina Carrera,Phillip Wong,Felix Quagliarello,Bradley Wubbenhorst,Kurt D'Andrea,Kristen E. Pauken,Ramin S. Herati,Ryan P. Staupe,Jason M. Schenkel,Suzanne McGettigan,Shawn Kothari,Sangeeth M. George,Robert H. Vonderheide,Ravi K. Amaravadi,Giorgos C. Karakousis,Lynn M. Schuchter,Xiaowei Xu,Katherine L. Nathanson,Jedd D. Wolchok,Tara C. Gangadhar,E. John Wherry +35 more
TL;DR: Blood profiling of peripheral blood from patients with stage IV melanoma before and after treatment with the PD-1-targeting antibody pembrolizumab is used to identify pharmacodynamic changes in circulating exhausted-phenotype CD8 T cells (Tex cells) and identify a clinically accessible potential on-treatment predictor of response to PD- 1 blockade.